Not Yet RecruitingNot Applicable

A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

United States150 participantsStarted 2025-05-01

Plain-language summary

The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause mortality.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients ≥ 18 years of age
✓. Uncomplicated candidemia (positive blood culture only). No evidence of invasive candidiasis at day 1 or until day 7.
✓. Received \< 5 days of prior antifungal therapy
✓. Informed Consent for randomization
✓. Patients that did not consent to randomization have consented to be used as a natural history (controls) and will allow collection of available data from the medical record.

Exclusion criteria

✕. Inadequate source control (e.g., unable to remove endovascular devices, urinary catheters).
✕. Invasive candidiasis of any type (e.g., deep seated candidiasis from sources other than blood)
✕. Abnormal LFTs \> 10-fold
✕. Greater than 5 days of prior antifungal therapy
✕. Endovascular devices that cannot be removed.
✕. Immunocompromised patients (AIDS/HIV; solid organ transplant, bone marrow transplant patients, oncology patients receiving chemotherapy, neutropenic patients (ANC of \< 1,500 cells/L
✕. Neutropenic at time of consent (what does this mean)
✕. Break-through candidemia (people with prior candidemia who relapsed) after treatment with antifungal therapy)

What they're measuring

Eradication of candida from the blood at day 7 or day 14

Timeframe: 14 Days

Trial details

NCT IDNCT06907992

SponsorAugusta University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-05-01

Contact for this trial

Aprile Osborn, MSN

706-721-0309 aosborn@augusta.edu

View on ClinicalTrials.gov More Candidemia trials